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 Abstract 
Transcriptomic imputation approaches offer an opportunity to test 
associations between disease and gene expression in otherwise inaccessible 
tissues, such as brain, by combining eQTL reference panels with large-scale 
genotype data. These genic associations could elucidate signals in complex 
GWAS loci and may disentangle the role of different tissues in disease 
development. 
Here, we use the largest eQTL reference panel for the dorso-lateral pre-
frontal cortex (DLPFC),collected by the CommonMind Consortium, to create a 
set of gene expression predictors and demonstrate their utility. We applied 
these predictors to 40,299 schizophrenia cases and 65,264 matched controls, 
constituting the largest transcriptomic imputation study of schizophrenia 
to date. We also computed predicted gene expression levels for 12 
additional brain regions, using publicly available predictor models from 
GTEx. We identified 413 genic associations across 13 brain regions. 
Stepwise conditioning across the genes and tissues identified 71 associated 
genes (67 outside the MHC), with the majority of associations found in the 
DLPFC, and of which14/67 genes did not fall within previously genome-wide 
significant loci. We identified 36 significantly enriched pathways, 
including hexosaminidase-A deficiency, and multiple pathways associated 
with porphyric disorders. We investigated developmental expression patterns 
for all 67 non-MHC associated genes using BRAINSPAN, and identified groups 
of genes expressed 
specifically pre-natally or post-natally. 
Introduction 
Genome-wide association studies (GWAS) have yielded large lists of disease-
associated loci.Despite this, progress in identifying the causal variants 
driving these associations, particularly for complex psychiatric disorders 
such as schizophrenia, has lagged much further behind. Interpreting 
associated variants and loci is therefore vital to understanding how 
genetic variation contributes to disease pathology. Expression Quantitative 
Trait Loci (eQTLs), which are responsible for a substantial proportion of 
gene expression variance, have been posited as a potential link between 
associated loci and disease susceptibility1–5, and indeed have yielded 
results for a host of complex traits6–9. Consequently, numerous methods to 
identify and interpret co-localisation of eQTLs and GWAS loci have been 
developed10–13. However, these methods require simplifying assumptions about 
genetic architecture (i.e., one causal variant per GWAS locus) and/or 
linkage disequilibrium, may be underpowered or overly conservative, 
especially in the presence of allelic heterogeneity, and have not yet 
yielded substantial insights into existing or novel loci. 
 
Biologically relevant information can be extracted by transcriptomic 
investigations, as recently described by the CommonMind Consortium14 (CMC), 
thanks to detailed RNA-sequencing in a large cohort of genotyped 
individuals with schizophrenia and bipolar disorder14. These analyses 
however are underpowered to detect with statistical confidence differential 
expression of genes mapping at schizophrenia (SCZ) risk loci, due to the 
small effects predicted by GWAS combined with the difficulty of obtaining 
adequate sample sizes of neurological tissues14. Still, such methods do not 
necessarily identify all risk variation in GWAS loci. Transcriptomic 
imputation is an alternative approach that leverages large eQTL reference 
panels to bridge the gap between large-scale genotyping studies and 
biologically useful transcriptome studies15,16. This approach seeks to 
identify and codify the relationships between genotype and gene expression 
in matched panels of individuals, then impute the genetic component of the 
transcriptome into large-scale genotype-only datasets, such as case-control 
GWAS cohorts, which enables investigation of disease-associated gene 
expression changes. This will allow us to study genes with modest effect 
sizes, likely representing a large proportion of genomic risk for 
psychiatric disorders14,17. 
The access to the large collection of dorso-lateral pre-frontal cortex 88 
(DLPFC) gene expression data collected by the CommonMind Consortium14 
affords us a unique opportunity to study and  codify relationships between 
genotype and gene expression. Here, we present a novel set of gene  
expression predictor models, built using CommonMind Consortium DLPFC 
data14. We compare different regression approaches to building these models 
(including elastic net15, Bayesian sparse  linear mixed models and ridge 
regression16, and using max eQTLs), and benchmark performance of these 
predictors against existing GTEx prediction models. We applied our CMC 
DLPFC predictors and 12 GTEx-derived neurological prediction models to 
predict gene expression in  schizophrenia GWAS data, obtained through 
collaboration with the Psychiatric Genomics Consortium (PGC) schizophrenia 
working group, the “CLOZUK2” cohort, and the iPSYCH GEMS schizophrenia 
working group. We identified 413 genome-wide significant genic  
associations with schizophrenia in our PGC+CLOZUK2 sample, constituting 67 
independent associations outside the MHC region. We demonstrate the 
relevance of these associations to schizophrenia aetiopathology using gene 
set enrichment analysis, and by examining the effects of manipulation of 
these genes in mouse models. Finally, we investigated spatio-temporal 
expression of these genes using a developmental transcriptome dataset, and 
identified distinct spatio-temporal patterns of expression across our 
associated genes. 
 
Results 
Prediction Models based on CommonMind Consortium DLPFC expression 
Using matched genotype and gene expression data from the CommonMind 
Consortium Project, we developed DLPFC genetically regulated gene 
expression (GREX) prediction models. We systematically compared four 
approaches to building predictors15,16 within a cross-validation framework. 
Elastic net regression had a higher distribution of cross-validation R2 
(RCV2) and higher mean RCV2 values (Supplementary Figures 1, 2A) than all 
other methods. We therefore used elastic net regression to build our 
prediction models. We compared prediction models created using elastic net 
regression on SVA-corrected and uncorrected data14. The distribution of Rcv2 
values for the SVA-based models was significantly higher than for the un-
corrected data14,18 (ks-test; p<2.2e-16; Supplementary figure 1B-C). In 
total, 10,929 genes were predicted with elastic net cross-validation Rcv2 > 
0.01 in the SVA-corrected data and were included in the final predictor 
database (mean Rcv2 = 0.076). 
 
To test the predictive accuracy of the CMC-derived DLPFC models, and to 
benchmark this against existing GTEx-derived prediction models, 
genetically-regulated gene expression (GREX) was calculated in an 
independent DLPFC RNA-sequencing dataset (the Religious Orders Study Memory 
and Ageing Project, ROSMAP19). We compared predicted GREX to measured 
ROSMAP gene expression for each gene (Replication R2, or RR2) for the CMC-
derived DLPFC models and twelve GTEx-derived brain tissue models15,20,21 
(Figure 1,Supplementary Figure133 2B). CMC-derived DLPFC models had higher 
average RR2 values (Mean RR2 = 0.056), more genes with RR2 > 0.01, and 
significantly higher overall distributions of RR2 values than any of the 
twelve GTEx models (ks-test, p<2.2x10-16 across all analyses; Figure 1). 
Median RR2 values were significantly correlated with sample size of the 
original tissue set (rho=0.92, p=7.2x10-6), the number of genes in the 
prediction model (rho=0.9, p=2.6x10-5), and the number of significant 
‘eGenes’ in each tissue type (rho=0.95, p=5.5x10-7; Figure 1C). Notably, 
these correlations persist after removing obvious outliers (Figure 1C). 
 
To estimate trans-ancestral prediction accuracy, genetically regulated gene 
expression was calculated for 162 African-American individuals and 280 
European individuals from the NIMH Human Brain Collection Core (HBCC) 
dataset (supplementary figure 2B). RR2 values were higher on average in 
Europeans than African-Americans (average 144 RR_EUR2 = 0.048, RR_AA2 = 
145 0.040), but were significantly correlated between African-Americans and 
Europeans (rho=0.78, p<2.2 x10-16, Pearson test; supplementary figure 3). 
 
Application of Transcriptomic Imputation to Schizophrenia 
We used CMC DLPFC and the 12 GTEx–derived brain tissue prediction models to 
impute genetically regulated expression levels (GREX) of 19,661 unique 
genes in cases and controls from the PGC-SCZ GWAS study22. Predicted 
expression levels were tested for association with schizophrenia. 
Additionally, we applied CMC and GTEx-derived prediction models to summary 
statistics from 11 PGC cohorts (for which raw genotypes were unavailable) 
and the CLOZUK2 cohort. Meta-analysis was carried out across all PGC-SCZ 
and CLOZUK2 cohorts using an odds-ratio based approach in METAL. Our final 
analysis included 40,299 cases and 65,264 controls (Figure 2A). 
 
We identified 413 genome-wide significant associations, representing 256 
genes in 13 tissues (Figure 3A). The largest number of associations were 
detected in the CMC DLPFC GREX data (Figure 3C; 49 genes outside the MHC, 
69 genes overall). We sought replication of our CMC DLPFC SCZ-associations 
in an independent dataset of 4,133 cases and 24,788 controls in 
collaboration with the iPSYCH-GEMS SCZ working group (Figure 2B). We found 
significant correlation of effect sizes (p=1.784 x10-04; rho=0.036) and –
log10 p-values (p=1.073 x10-05;rho=0.043) between our discovery 
(PGC+CLOZUK2) and replication (iPSYCH-GEMS) 
165 samples. Non-MHC Genes reaching genome-wide significance in our 
discovery sample (49 genes) were significantly more likely to reach nominal 
significance in the replication sample, and had significantly more 
consistent directions of effect than might be expected by chance (binomial 
test, p=2.42 x10-05, p=0.044). (Suppl. info). 
 
To identify the top independent associations within genomic regions, which 
include multiple associations for a single gene across tissues, or multiple 
nearby genes, we partitioned genic associations into 58 groups defined 
based on genomic proximity and applied stepwise forward conditional 
analysis within each group (Supplementary Table 1). In total, 67 genes 
remained genome-wide significant after conditioning (Table 1; Figure 3A-B). 
The largest signal was identified in the CMC DLPFC predicted expression 
data (24 genes; Figure 3C), followed by the Putamen (7 genes). 19/67 genes 
did not lie within 1Mb of a previously genome-wide significant GWAS locus22 
(shown in bold, Table 1); of these, 5/19 genes were within 1Mb of a locus 
which approached genome-wide significance (p<5x10-07). The remaining 14 
genes all fall within nominally significant PGC-SCZ GWAS loci (p<8x10-04), 
but did not reach genome-wide significance. 
 
Implicated genes highlight SCZ-associated molecular pathways and gene set 
analyses  
We tested for overlap between our non-MHC SCZ-associated genes and 8,657 
genesets comprised of 1) hypothesis-driven pathways and 2) general 
molecular database pathways. We corrected for multiple testing using the 
Benjamin-Hochberg false discovery rate (FDR) correction23. 
 
We identified three significantly associated pathways in our hypothesis-
driven analysis (Table 2). Targets of the fragile-X mental retardation 
protein formed the most enriched pathway (FMRP; p=1.96x10-8). Loss of FMRP 
inhibits synaptic function, is comorbid with autism spectrum disorder, and 
causes intellectual disability, as well as psychiatric symptoms including 
anxiety, hyperactivity and social deficits24. Enrichment of this large 
group of genes has been observed frequently, in the original CommonMind 
analysis14, by colleagues investigating the same PGC and CLOZUK2 samples26 
as well as by investigators studying autism24,27. There was a significant 
enrichment among our SCZ associated genes and genes that have been shown to 
be intolerant to loss-of-function mutations28 (p=5.86x10-5) as well as with 
CNVs associated with bipolar disorder29 (p=7.92x10-8), in line with a recent 
variant-based study of the same individuals26. 
 
Next, we performed an agnostic search for overlap between our 
schizophrenia-associated genes and ~ 8,500 molecular pathways collated from 
large, publicly available databases. 33 pathways were significantly 
enriched after FDR correction (Table 2, Suppl. Table 2), including a number 
of pathways with some prior literature in psychiatric disease. We 
identified an enrichment with porphyrin metabolism (p=1.03x10-4). 
Deficiencies in porphyrin metabolism lead to “Porphyria”, an adult-onset 
metabolic disorder with a host of associated psychiatric symptoms, in 
particular episodes of violence and psychosis30–35. Five pathways 
potentially 206 related to porphyrin metabolism, regarding abnormal iron 
level in the spleen, liver and kidney are also significantly enriched, 
including 2/5 of the most highly enriched pathways (p<2.0 x10-04). The 
PANTHER and REACTOME pathways for Heme biosynthesis and the GO pathway for 
protoporphyrinogen IX metabolic process, which are implicated in the 
development of porphyric disorders, are also highly enriched (p=2.2 x10-04, 
2.6 x10-04, 4.1 x10-04), although do not pass FDR-correction. 
 
 Hexosaminidase activity was enriched (p=3.47 x10-05) in our results; this 
enrichment is not driven by a single highly-associated gene; rather, every 
single gene in the HEX-A pathway is nominally significant in the SCZ 
association analysis (Supplementary Table 2). Deficiency of hexosaminidase 
A (HEX-A) results in serious neurological and mental problems, most 
commonly presenting in infants as “Tay-Sachs” disease36. Adult-onset HEX-
A deficiency presents with neurological and psychiatric symptoms, notably 
including onset of psychosis and schizophrenia37. Five pathways 
corresponding to Ras- and Rab- signaling, protein regulation and GTPase 
activity were enriched (p<6x10-05). These pathways have a crucial role in 
neuron cell differentiation38 and migration39, and have been implicated in 
the development of schizophrenia and autism40–43. We also find significant 
enrichment with protein phosphatase type 2A regulator activity (p=5.24x10-
05), which was associated with MDD and across MDD, BPD and SCZ in the same 
large integrative analysis44, and has been implicated in antidepressant 
response and serotonergic neurotransmission45. 
 
Predicted gene expression changes are consistent with functional validation 
studies 
 To test the functional impact of our SCZ-associated predicted gene 
expression changes (GREX), we performed two in-silico analyses. First, we 
compared directions of effect in our meta-analysis to those in the CMC 
analysis of differentially expressed genes between SCZ cases and controls. 
This analysis highlighted six loci where expression levels of a single gene 
putatively affected schizophrenia risk. All six of these genes are 
nominally significant in our DLPFC analysis, and two (CLCN3 and FURIN) 
reach genome-wide significance. In the conditional analysis across all 
brain regions, one additional gene (SNX19) reaches genome-wide 
significance. The direction of effect for all six genes matches the 
direction of gene expression changes observed in the original CMC paper, 
indicating that gene expression estimated in the imputed transcriptome 
reflects measured expression levels in brains of individuals with 
Schizophrenia. Further, this observation is consistent with a model where 
the differential expression signature observed in CMC is caused by genetics 
rather than environment. 
 
The original CMC analysis identified 21 eSNP genes using SHERLOCK14,46, of 
which 17 were present in our CMC DLPFC analysis. 14/17 genes reached 
nominal significance (significantly more than expected by chance, p=3.6x10-
16), and 11 reached genome-wide significance (binomial p-value 6.04x10-55). 
Additionally, 31 regions contained genes ranked highly by Sherlock in the 
original CMC analysis (supplementary data file 2 in Fromer, M. et al. Gene 
expression elucidates functional impact of polygenic risk for 
schizophrenia. Nat. Neurosci. 19, 1442–1453 (2016)14). Of these, 14 regions 
lay near one of our CMC DLPFC associated genes,and 13/14 regions had common 
genes between SHERLOCK and PrediXcan analyses. Five loci included multiple 
SHERLOCK genes; in every instance we are able to specifically identify one 
or two associated genes from the longer SHERLOCK list. 
 
To understand the impact of altered expression of our 67 SCZ-associated 
genes, we performed an in-silico analysis of mouse mutants, by collating 
large, publicly available mouse databases47– 51. We identified mutant mouse 
lines lacking expression of 37/67 of our SCZ-associated genes,and obtained 
5,333 phenotypic data points relating to these lines, including 1,170 
related to behavioral, neurological or craniofacial phenotypes. 25/37 genes 
were associated with at least one behavioral, neurological or related 
phenotype (Supplementary table 3). We repeated this analysis for genes 
identified in 366 GWAS, including any GWAS for which at least ten mutant 
mouse lines exist (105 GWAS). SCZ-associated genes were more likely to be 
associated with behavior, brain development and nervous system phenotypes 
than genes in these GWAS sets (p=0.057). 
 
Spatiotemporal expression of SCZ-associated genes indicated distinct 
patterns of risk throughout development 
We assessed expression of our SCZ-associated genes throughout development 
using BRAINSPAN52. Data were partitioned into eight developmental stages 
(four pre-natal, four postnatal), and four brain regions29,52 (Figure 4A). We 
noted that SCZ-associated genes were significantly co-expressed, in both 
pre-natal and post-natal development and in all four brain regions, based 
on local connectedness53 (Figure 4B), global connectedness53 (i.e., average 
path length between genes, supplementary Figure 6), and network density 
(i.e., number of edges,  supplementary Figure 7). Examining pairwise gene 
expression correlation (suppl. Fig 8) and  gene co-expression networks 
(suppl. Fig 9) for each spatiotemporal point indicated that the same  genes 
do not drive this co-expression pattern throughout development; rather, it 
appears that separate groups of genes drive early pre-natal, late pre-natal 
and post-natal clustering. 
To visualize this, we calculated Z scores of gene expression for each SCZ-
associated gene, across all 32 time-points (Figure 5). Genes clustered into 
four groups (supplementary fig 10), with distinct spatio-temporal 
expression signatures. The largest cluster (Cluster A, Figure 5A; 29 genes) 
spanned early to late-mid pre-natal development (4-24 weeks post 
conception), either across the whole brain (22 genes) or in regions 1-3 
only (7 genes). 12 genes were expressed in late pre-natal development 
(Figure 5D; 25-38 pcw); 10 genes were expressed in regions 1-3, post-
natally and in the late pre-natal period (Figure 5C), and 15 genes were 
expressed throughout development (Figure 5B), either specifically in region 
four (nine genes) or throughout the brain (six genes). We used a stratified 
qq-plot approach54 to examine whether SNPs in cis-regions of genes in these 
four clusters are differentially enriched in psychiatric disorders. SNPs in 
cis regions of genes in the two pre-natal clusters are more highly enriched 
than SNPs in cis-regions of genes in post-natal clusters, and compared to 
all SNPs, in childhood-onset disorders (ASD and 
ADHD, supplementary figure 13), but not adult-onset disorders (BPD and MDD, 
data not shown). 
 
We noticed a relationship between patterns of gene expression and the 
likelihood of behavioral, neurological or related phenotypes in our mutant 
mouse model database. Mutant mice lacking genes expressed exclusively 
prenatally in humans, or genes expressed pre- and postnatally, were more 
likely to have any behavioral or neurological phenotypes than mutant mice 
lacking expression of genes expressed primarily in the third trimester or 
postnatally (p=1.7x10-04) (supplementary figure 11). 
 
Discussion 
In this study, we present gene expression prediction models for the 
dorsolateral pre-frontal cortex (DLPFC), constructed using Common Mind 
Consortium genotype and gene expression data. These prediction models may 
be applied to either raw data or summary statistics, in order to yield gene 
expression information in large data sets, and across a range of tissues. 
This has the significant advantage of allowing researchers to access 
transcriptome data for non-peripheral tissues, at scales currently 
prohibited by the high cost of RNA sequencing, and circumventing 
distortions in measures of gene expression stemming from errors of 
measurement or environmental influences. Since disease status may alter 
gene expression but not the germline profile, analyzing genetically 
regulated expression ensures that we identify only the causal direction of 
effect between gene expression and disease15. Large, imputed transcriptomic 
datasets represent the first opportunity to study the role of subtle gene 
expression changes (and therefore modest effect sizes) in disease 
development. 
 
There are some inherent limitations to this approach. The accuracy of 
transcriptomic imputation (TI) is reliant on access to large eQTL reference 
panels, and it is therefore vital that efforts to collect and analyze these 
samples continue. TI has exciting advantages for gene discovery as well as 
downstream applications15,55,56; however, the relative merits of existing 
methodologiesare as yet under-explored. Our analysis suggests that, 
overall, sparser elastic net models better capture gene expression 
regulation than BSLMM; at the same time, the improved performance of 
319 elastic net over max-eQTL models suggests that a single eQTL model is 
over-simplified2,15. 
Fundamentally, transcriptomic imputation methods model only the genetically 
regulated portion of gene expression, and so cannot capture or interpret 
variance of expression induced by environment or lifestyle factors, which 
may be of particular importance in psychiatric disorders. Given the right 
study design, analyzing genetic components of expression together with 
observed expression could open doors to better study the role of gene 
expression in disease. 
 
Sample size and tissue matching contribute to accuracy of TI results. Our 
CMC-derived DLPFC prediction models had higher average validation R2 values 
in external DLPFC data than GTEx328 derived brain tissue models. Notably, 
the model with the second highest percent of genes passing the R2 threshold 
is the Thyroid, which has the largest sample size among the GTEx brain 
prediction models. When looking at mean R2 values, the second highest value 
330 comes from the GTEx Frontal Cortex, despite the associated small sample 
size, implying at least some degree of tissue specificity of eQTLs 
architecture. 
 
We were able to compare TI accuracy in European and African-American 
individuals, and found that our models were applicable to either ethnicity 
with only a small decrease in accuracy. Common SNPs shared across 
ethnicities have important effects on gene expression, and as such we 
expect GREX to have consistency across populations. There is a well-
documented dearth of exploration of genetic associations in non-European 
cohorts57,58 We believe that these analyses should be carried out in non-
European cohorts. 
 
 We applied the CMC DLPFC prediction models, along with 12 GTEx-derived 
brain expression prediction models, to schizophrenia cases and controls 
from the PGC2 and CLOZUK2 collections, constituting the largest 
transcriptomic analysis of schizophrenia to date. Predicted gene expression 
levels were calculated for 19,661 unique genes across brain regions (Figure 
1C) and tested for association with SCZ case-control status. We identified 
413 significant associations, constituting 67 independent associations. We 
found significant replication of our CMC DLPFC associations in a large 
independent replication cohort, in collaboration with the iPSYCH-GEMS 
consortium. A recent TWAS study of 30 GWAS summary statistic traits55 
identified 38 non-MHC genes associated at tissue-level significance with 
SCZ in CMC- andGTEx-derived brain tissues (ie, matching those used in our 
study). Of these, 26 also reach genome-wide significance in our study, 
although in many instances these genes are not identified as the lead 
independent associated gene following our conditional analysis. Among our 
67 SCZ353 associated genes, 19 were novel, i.e. did not fall within 1Mb of 
a previous GWAS locus (including 5/7 of the novel brain genes identified in 
the recent TWAS analysis). 
 
 We used conditional analyses to identify independent associations within 
loci. These analyses clarify the most strongly associated genes and tissues 
(Table 1), while we note that nearly collinear gene-tissue pairs could also 
represent causal associations. The tissues highlighted allowed us to 
tabulate apparently independent contributions to SCZ risk from different 
brain regions, even though their transcriptomes are highly correlated 
generally. 360 We find DLPFC and Cerebellum effects, as well as from 
Putamen, Caudate and Nucleus Accumbens Basal Ganglia. 
 
We used these genic associations to search for enrichments with molecular 
pathways and gene sets, and identified 36 significant enriched pathways. 
Among novel pathways, we identified a significant association with HEX-A 
deficiency. Despite the well-studied and documented symptomatic overlap 
between adult-onset HEX-A deficiency and schizophrenia, we believe that 
this is the first demonstration of shared genetics between the disorders. 
Notably, this overlap is not driven by a single highly-associated gene 
which is shared by both disorders; rather, every single gene in the HEX-A 
pathway is nominally significant in the SCZ association analysis, and five 
genes have p < 1x10-03, indicating that there may be substantial shared 
genetic aetiology between the two disorders that warrants further 
investigation. Additionally, we identified a significant overlap between 
our SCZ-associated genes and a number of pathways associated with porphyrin 
metabolism. Porphyric disorders have been well characterized and are among 
early descriptions of “schizophrenic” and psychotic presentations of 
schizophrenia, as described in the likely eponymous mid-19th century poem 
“Porphyria’s Lover”, by Robert Browning59, and have been cited as a 
likely diagnosis for the various psychiatric and metabolic ailments of 
Vincent van Gogh60–65 and King George III66. 
 
Finally, we assessed patterns of expression for the 67 SCZ-associated genes 
throughout development using spatio-temporal transcriptomic data obtained 
from BRAINSPAN. We identified four clusters of genes, with expression in 
four distinct spatiotemporal regions, ranging from early pre-natal to 
strictly post-natal expression. There are plausible hypotheses and genetic 
evidence for SCZ disease development in adolescence, given the correlation 
with age of onset, as well as prenatally, supported by genetic overlap with 
neurodevelopmental disorders67–69 as well as the earlier onset of cognitive 
impairments70–73. Understanding the temporal expression patterns of SCZ-
associated genes can help to elucidate gene development and trajectory, and 
inform research and analysis design. Identification of SCZ-associated genes 
primarily expressed prenatally is striking given our adult eQTL reference 
panels, and may reflect common eQTL architecture across development, which 
is known to be partial74–76; therefore, our results should spur interest in 
extending TI data and/or methods to early development74. Identification of 
SCZ-associated genes primarily expressed in adolescence and adult-hood is 
391 of particular interest for direct analysis of the brain transcriptome 
in adult psychiatric cases. 
 
eQTL data have been recognized for nearly a decade as potentially important 
for understanding complex genetic variation. Nicolae et al1 showed that 
common variant-common disease associations are strongly enriched for 
genetic regulation of gene expression. Therefore, integrative approaches 
combining transcriptomic and genetic association data have great potential. 
Current TI association analyses increase power for genetic discovery, even 
while many open areas of TI remain to be developed, such as leveraging 
additional data types such as chromatin modifications77 (e.g. methylation, 
histone modification), imputing different tissues or  different exposures 
(e.g. age, smoking, trauma) and modeling trans/coexpression effects. It 
remains critical to leverage TI associations to provide insights into 
specific disease mechanisms. Here, the accelerated identification of 
disease associated genes allows the detection of novel pathways and 
distinct spatiotemporal patterns of expression in schizophrenia risk. 
 
Online Methods (Limit 3,000 words, at end of manuscript, c 407 urrently 2,064) 
 
Creating gene expression predictors for the dorso-lateral pre-frontal cortex 
eQTL Data 
Genotype and RNAseq data were obtained for 538 European individuals through 
the 
CommonMind Project14. RNA-seq data were generated from post-mortem human 
dorsolateral prefrontal cortex (DLPFC). The gene expression matrix was 
normalized to log (counts permillion) using voom. Adjustments were made for 
known covariates (including sample415 ascertainment, quality, experimental 
parameters, ancestry) and surrogate variables, using linear 416 modelling 
with voom-derived regression weights. Details on genotyping, imputation and 
RNA417seq generation may be found in the CommonMind Consortium flagship 
paper14. 
 
A 1% MAF cut-off was applied. Variants were filtered to remove any SNPs in 
high LD (r2>0.9), indels, and all variants with ambiguous ref/alt alleles. 
All protein coding genes on chromosomes 1-22 with at least one cis-SNP 
after these QC steps were included in this analysis. SNPs in trans have 
been shown not to provide a substantial improvement in prediction 
accuracy15 and were not included here. 
 
Building gene expression prediction databases 
Gene expression prediction models were created following the “PrediXcan” 
method15. Matched genotype and gene expression data were used to identify a 
set of variants that influence gene expression (Supplementary Figure 2A). 
Weights for these variants are calculated using regression in a ten-fold 
cross-validation framework. All cross-validation folds were balanced for 
diagnoses, ethnicity, and other clinical variables. 
 
All SNPs within the cis-region (+/- 1mb) of each gene were included in the 
regression analysis. Accuracy of prediction was estimated by comparing 
predicted expression to measured expression, across all 10 cross-validation 
folds; this correlation was termed cross-validation R2 or Rcv2. Genes with 
Rcv2 > 0.01 (~p<0.05) were included in our final predictor database. 
 
Prediction models were compared across four different regression 437 
methods; elastic net (prediXcan), ridge regression (using the TWAS 
method16), Bayesian sparse linear mixed modelling (BSLMM; TWAS), and linear 
regression using the best eQTL for each gene (Supplementary Figure 1A). 
Mean Rcv2 values were significantly higher for elastic net regression (mean 
Rcv2=0.056) than for eQTL-based prediction (mean Rcv2=0.025), BSLMM (mean 
Rcv2=0.021) or Ridge Regression (mean Rcv2=0.020). The distribution of Rcv2 
values was also significantly higher for elastic net regression than for 
any other method (ks-test, p<2.2x10-16). 
 
Replication of gene expression prediction models in independent data 
Predictive accuracy of CMC DLPFC models were tested in two independent 
datasets.First, we used data from the Religious Orders Study and Memory and 
Aging Project 
(ROSMAP19). This study included genotype data and DLPFC RNA-seq data78 for 
individuals of European descent (Supplementary Figure 2B). 
 
DLPFC genetically-regulated expression (GREX) was calculated using the CMC 
DLPFC predictor models. Correlation between RNA-seq expression and CMC 
DLPFC GREX (“Replication R2 values” or RR2) was used as a measure of 
predictive accuracy. RR2 was calculated including correction for ten 
ancestry components, as follows: 
 
Equation 1: RR2 calculation. ��1 
 2 = (� ~ ���� + ��1 + ��2 +⋯+ ��10) ��2 
 2 = (� ~ ��1 + ��2 + ⋯+ ��10) �� 2 = ��1 
2 -��2 
 2 
 
Where: � Measured expression (RNA-seq) ���� GREX imputed expression ��� nth Principal Component 
 
A small number of genes (158) had very low predictive accuracy and were 
removed from further analyses. Cross-validation R2 (Rcv2) values and RR2 
values were highly correlated (rho=0.62,464 p<2.2e-16; Supplementary Figure 
3A). 55.7% of CMC DLPFC genes had RR2 values > 0.01. 
 
Prediction accuracy was also assessed for 11 publicly available GTEx 
neurological predictor databases, and RR2 values used to compare to CMC 
DLPFC performance. CMC DLPFC models had higher average RR2 values, more 
genes with RR2 > 0.01, and significantly higher overall distributions of 
RR2values than any of the twelve GTEx brain tissue models (ks-test, p<2.2e-
16;Figure 1A,B). 
 To estimate trans-ancestral prediction accuracy, genetically regulated gene 
expression was calculated for 162 African-American individuals and 280 
European individuals from the NIMH Human Brain Collection Core (HBCC) 
dataset79 (Supplementary Figure 2C). Predicted gene expression levels were 
compared to DLPFC expression levels measured using microarray. There was a 
significant correlation between the European and African-American samples 
for RCV2 values and RR2 values (rho=0.66, 0.56; Supplementary figure 3B-C). 
RR2 values were higher on average in Europeans, but were significantly 
correlated between African-Americans and Europeans (rho=0.78, p<2.2e-16, 
Pearson test; supplementary figure 3D). 
 
Extension to Summary Statistics 
Transcriptomic Imputation may be applied to summary statistics instead of 
raw dosages, in instances where raw data is unavailable. However, this 
method suffers from slightly reduced accuracy, requires covariance matrices 
calculated in an ancestrally-matched reference population80 (usually only 
possible for European cohorts), and precludes testing of 
endophenotypes within the data, and so should not be applied when raw data 
is available. 
 
We assessed concordance between CMC DLPFC transcriptomic imputation results 
using summary-statistics (MetaXcan80) and raw genotypes (PrediXcan15) using 
nine European and three Asian PGC-SCZ cohorts22 for which both data types 
were available. Cohorts were chosen to encompass a range of case : control 
ratios, to test previous suggestions that accuracy isreduced in unbalanced 
cohorts80. Covariances for all variants included in the DLPFC predictor 
models were computed using MetaXcan80. For all European cohorts, Pearson 
correlation of log-10 p-values and effect sizes was above 0.95. The mean 
correlation was 0.963 (Supplementary Figure 4). There was no correlation 
between total sample size, case-control ratio, p-value or 
effect-size. Seven genes were removed due to discordant p-values. For 496 
the three Asian cohortstested, the mean correlation was 0.91 (Supplementary 
Figure 5). 
 
Concordance was also tested for the same nine European PGC-SCZ cohorts, 
across 12 neurological GTEx prediction databases. All correlations were 
significant (rho>0.95, p<2.2e-16).There was a significant correlation 
between p-value concordance and case-control ratio (rho=0.37, p=7.606 x10-
15). 114 genes had discordant p-values between the two methods and were 
excluded from future analyses. 
 
Application to Schizophrenia Dataset Collection 
We obtained 53 discovery cohorts for this study, including 40,299 SCZ cases 
and 65,264 controls (Figure 2). 52/53 cohorts (35,079 cases, 46,441 
controls) were obtained through collaboration with the Psychiatric Genomics 
Consortium, and are described in the 2014 PGC Schizophrenia GWAS22. The 
remaining cohort, referred to as CLOZUK2, constitutes the largest single 
cohort of individuals with Schizophrenia (5,220 cases and 18,823 controls), 
collected as part of an effort to investigate treatment-resistant 
Schizophrenia26. 
 
50/53 datasets included individuals of European ancestry, while three 
datasets include individuals of Asian ancestry (1,836 cases, 3,383 
controls). All individuals were ancestrally matched to controls. 
Information on genotyping, quality control and other data management issues 
may be found in the original papers describing these collections22,26. All 
sample collections complied with ethical regulations. Details regarding 
ethical compliance and consent procedures may be found in the original 
manuscripts describing these collections22,26. 
 
Access to dosage data was available for 44/52 PGC-SCZ cohorts. The 
remaining PGC cohorts, and the CLOZUK2 cohort provided summary statistics. 
Three European PGC cohorts were trio based, rather than case-control. 
 
Additionally, we tested for replication of our CMC DLPFC associations in an 
independent dataset of 4,133 cases and 24,788 controls obtained through 
collaboration with the iPSYCH-GEMS schizophrenia working group (effective 
sample size 14,169.5; Figure 2B, supplementary information). 
 
Transcriptomic Imputation and association testing 
Transcriptomic Imputation was carried out individually for each case-
control PGC-SCZ cohort with available dosage data (44/52 cohorts). 
Predicted gene expression levels were computed using the DLPFC predictors 
described in this manuscript, as well as for 11 other brain tissues 
prediction databases created using GTEx tissues15,20,21,81 (Figure 1C). 
Associations between predicted gene expression values and case-control 
status were calculated using a linear regression test in R. Ten ancestry 
principal components were included as covariates. Association tests were 
carried out independently for each cohort, across 12 brain tissues. 
 
For the 8 PGC cohorts with no available dosage data, the three PGC trio-
based analyses, and the CLOZUK2 cohort, a summary-statistic based 
transcriptomic imputation approach was used (“MetaXcan”), as described 
previously. 
 
Meta-analysis 
Meta-analysis was carried out across all 53 cohorts using METAL82. 
Cochran’s Q test for heterogeneity was implemented in METAL82,83, and a 
heterogeneity p-value threshold of p > 1x10-3 applied to results. A 
conservative significance threshold was applied to these data, correcting 
for the total number of genes tested across all tissues (121,611 gene-
region tests in total). This resulted in a genome-wide significance 
threshold of 4.1x10-7. 
 
 Effect sizes and direction of effect quoted in this manuscript refer to 
changes in predicted expression in cases compared to controls i.e., genes 
with negative effect sizes have decreased predicted expression in cases 
compared to controls. 
 
Identifying independent associations 
We identified a number of genomic regions which contained multiple gene 
associations and/or genes associated across multiple tissues. We identified 
58 of these regions, excluding the MHC, based on distance between 
associated genes, and verified them using visual inspection. In order to 
identify independent genic associations within these regions, we carried 
out a stepwiseforward conditional analysis following “GCTA-COJO” theory84 
using “CoCo” (https://github.com/theboocock/coco/), an R implementation 
of GCTA-COJO. CoCo allows the specification of custom correlation matrices 
by the user (for example, ancestrally specific LD matrices). For each 
region, we generated a predicted gene expression correlation matrix for all 
significant genes (p≤ 1x10-6), as the root-effective sample size (Neff, eqn 
2) weighted average correlation across all cohorts where we had access to 
dosage data. 
Equation 2: Effective Sample Size, ���� 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Forward stepwise conditional analysis of all significant genes was carried 
out using joint linear regression modeling. First, the top-ranked gene was 
added to the model, then the next most significant gene in a joint model is 
added if significant at a given p-value threshold, and so on until either 
all genes are added to the model, or no joint statistic reaches the 
significance threshold. 
 
We calculated effect sizes and odds ratios for SCZ-associated genes by 
adjusting “CoCo” betas to have unit variance (Table 1, eqn. 3). 
 
 Equation 3: GREX Beta adjustment 
 � = ����� � √���� 
 
 
Where GVAR is the variance of the GREX predictor for each gene. 
 
Gene set Analyses 
Pathway analyses were carried out using an extension to MAGMA85. P-values 
were assigned togenes using the most significant p-value achieved by each 
gene in the meta-analysis. We then 
carried out a competitive gene-set analysis test using these p-values, 
using two gene sets: 
 
1. 159 gene sets with prior hypotheses for involvement in SCZ development, 
including loss of-function intolerant genes, CNV-intolerant genes, targets 
of the fragile-X mental retardation protein, CNS related gene sets, and 104 
behavioural 588 and neurological pathways from the Mouse Genome Informatics 
database14,26,67,86. 
2. An agnostic analysis, including ~8,500 gene sets collated from publicly 
available 
databases including GO87,88, KEGG89, REACTOME90, PANTHER91,92, BIOCARTA93 and 
MGI48. Sets were filtered to include only gene sets with at least ten 
genes. 
 
Significance levels were adjusted across all pathways included in either 
test using the Benjamini-Hochberg “FDR” correction in R23. 
 
Coexpression of SCZ genes throughout development 
We investigate spatiotemporal expression of our associated genes using 
publicly available developmental transcriptome data, obtained from the 
BRAINSPAN consortium94. We partitioned these data into biologically 
relevant spatio-temporal data sets95, corresponding to four general brain 
regions; the frontal cortex, temporal and parietal regions, sensory-motor 
regions, and subcortical regions (Figure 4A96), and eight developmental 
time-points (four pre-natal, four postnatal)95. 
 
First, we tested for correlation of gene expression for all SCZ-associated 
genes at each spatiotemporal time-point. Genes with pearson correlation 
coefficients >= 0.8 or <=-0.8 were considered co-expressed. 100,000 
iterations of this analysis were carried out using random gene sets with 
equivalent expression level distributions to the SCZ-associated genes. For 
each gene set, a gene co-expression network was created, with edges 
connecting all co-expressed genes. 
Networks were assessed using three criteria; first, the number of edges 
within the network, as a crude measured of connectedness; second, the 
Watts-Strogatz average path length between nodes, as a global measure of 
connectedness across all genes in the network53; third, the Watts- Strogatz 
clustering coefficient, to measure tightness of the clusters within the 
network53. For each spatio-temporal time point, we plotted gene-pair 
expression correlation (suppl. Fig 8) and co-expression networks (suppl. 
Fig 9). 
 
For each of the 67 SCZ-associated genes, we calculated average expression 
at each spatiotemporal point. We then calculated Z-Score of expression 
specificity using these values, and plotted Z-Scores to visually examine 
patterns of gene expression throughout 619 development and across brain 
regions. Clusters were formally identified using a dendrogram cut at height 
10 (Suppl. Fig 10). 
 
In-silico replication of SCZ-associated genes in mouse models 
We downloaded genotype, knock-out allele information and phenotyping data 
for ~10,000 mouse mutant models from five large mouse phenotyping and 
genotyping projects; Mouse Genome Informatics (MGI48), EuroPhenome47,97, 
Mouse Genome Project (MGP47,49), International Mouse Phenotyping Consortium 
(IMPC50), and Infection and Immunity Immunophenotyping (3I98). Where 
possible, we also downloaded raw phenotyping data regarding specific 
assays. In total, we obtained 175,012 phenotypic measurements, across 
10,288 mutant mouse models. We searched for any mouse lines with phenotypes 
related to behavior (natural, observed, stereotypic or assay-induced); 
cognition or working memory; brain, head or craniofacial dysmorphology; 
retinal or eye morphology, and/or vision or visual dysfunction or 
impairment; ear morphology or hearing dysfunction or impairment; neural 
tube defects; brain and/or nervous system development; abnormal 
nociception. 
 
We compared the prevalence of psychiatric phenotypes in mutant mice for our 
SCZ-associated genes to the prevalence among other disease-associated gene 
sets. We selected 366 GWAS gene sets, and removed any for which fewer than 
ten mutant mouse models were included in our databases, leaving 105 gene 
sets. We compared the prevalence of 13 different categories of psychiatric 
phenotypes, relating to adrenal gland, behavior, brain development, 
craniofacial dysmorphology, ear/auditory phenotypes, eye dysmorphology, 
head dysmorphology, nervous system development, abnormal nociception, 
seizures, thyroid gland, vision phenotypes. For each GWAS gene set, we 
counted the number of categories with at least one phenotype, and compared 
to the number in our SCZ-associated gene set to obtain an empirical p-
value. 
 
Data Availability 
Our CMC-derived DLPFC prediction models will be made publicly available. 
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Figure 1: Replication of DLPFC prediction models in independent data. 
Measured gene expression (ROSMAP RNA-seq) was compared to predicted 
genetically-regulated gene expression for CMC DLPFC and 12 GTeX predictor 
databases. Replication R2 values are significantly higher for the DLPFC 
than for the 12 GTEX brain expression models. 
 
A. Distribution of RR2 values of CMC DLPFC predictors in ROSMAP data. Mean 
RR 2 = 0.056. 47.7% of genes have RR 2 >= 0.01. 
B. Distribution of RR 2 values of 12 GTeX predictors in ROSMAP data. 
C. Table of sample sizes and p-val thresholds for CMC DLPFC and GTeX data. 
Number of samples, number of genes in the prediXcan model and number of 
eGenes are all significantlycorrelated with predictor performance in ROSMAP 
data. 
 
  
 
Figure 2: Analysis outline. 
A) Discovery Samples. 41 PGC-SCZ cohorts had available raw genotypes 
(i). Predicted DLPFC gene expression was calculated in each cohort using 
prediXcan (ii) and tested for association with case-control status 
(iii). 11 PGC cohorts (3 trio, 8 case-control) and the CLOZUK2 cohort 
had only summary statistics available (iv). MetaXcan was used to 
calculate DLPFC associations for each cohort (v). Results were meta-
analysed across all 53 cohorts (vi). This procedure was repeated for 12 
GTEx prediction models. 
B) Replication Samples. iPSYCH-GEMS samples were collected in 25 waves 
(i). Predicted DLPFC gene expression was calculated in each wave 
separately using prediXcan (ii) and merged for association testing 
(iii). A mega-analysis was run across all 25 waves, using wave 
membership as a covariate in the regression (iv) 
  
 
Figure 3: SCZ associations results 
A) 413 genes are associated with SCZ across 12 brain tissues 
B) 67 genes remain significant outside the MHC after stepwise conditional 
analysis 
C) Number of genome-wide significant loci, outside the MHC region, 
identified in each brain region. Abbreviations are as follows; CB- 
Cerebellum; CX- Cortex; FL- Frontal Cortex; DLPFC- Dorso-lateral pre-
frontal cortex; CB HEMI- Cerebellar Hemisphere; HIP- Hippocampus; PIT- 
Pituitary Gland; HTH- Hypothalamus; NAB- Nucleus Accumbens (Basal Ganglia); 
PUT- Putamen (Basal Ganglia); CAU- Caudate (Basal Ganglia); CNG- Anterior 
Cingulate Cortex 
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Figure 4: SCZ-associated genes are co-expressed throughout development 
and across brain regions 
A) Brain tissues selected for each of four BRAINSPAN regions. Region 1: 
IPC, V1C, ITC, OFC, STC, A1C; Region 2:S1C, M1C, DFC, VFC, MFC; Region 
3:HIP, AMY, STR; Region 4: CB 
B) Average clustering coefficients were calculated for all pairs of SCZ-
associated genes, and compared to permuted gene networks to obtain 
empirical significance levels. 
 
  
 
Figure 5: Gene expression patterns for SCZ-associated genes cluster into four 
groups, relating to distinct spatiotemporal expression. 
Brain regions are shown in figure 5a. 
A. 29 genes are expressed in the early-mid pre-natal period (4-24 post-
conception weeks) 
B. 15 genes are expressed throughout development; sub-clusters correspond 
to either specific expression in region 4, or expression across the brain 
C. Ten genes are expressed in the late-prenatal (25-38pcw) and post-natal 
period 
D. 12 genes are expressed in the late pre-natal period (25-39pcw) 



 
  
